二、监事会会议审议情况 证券代码：301331 证券简称：恩威医药 公告编号：2025-005 恩威医药股份有限公司 第三届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 恩威医药股份有限公司（以下简称"公司"）第三届监事会第六次会议通知 于 2025 年 4 月 8 日以邮件、微信方式发出，会议于 2025 年 4 月 18 日以现场方 式在公司办公楼会议室召开。本次会议应参会监事 3 名，实际参会监事 3 名。会 议由监事会主席杜长宏先生主持召开。本次会议的召开符合《公司法》和《公司 章程》的有关规定，所做决议合法有效。 1、审议通过《关于<2024 年度监事会工作报告>的议案》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）上的相关公 告。 表决结果为：同意 3 票，反对 0 票，弃权 0 票。 本议案尚需提交公司 2024 年年度股东大会审议。 2、审议通过《关于<2024 年度财务决算报告>的议案》 监事会认为：该决算报告客观、真实地反映了公司 2024 年度的财务状况和 ...

一、董事会会议召开情况 恩威医药股份有限公司（以下简称"公司"）第三届董事会第六次会议于 2025 年 4 月 8 日以电子邮件、微信等方式通知全体董事，于 2025 年 4 月 18 日以现 场及通讯方式在公司会议室召开。本次会议应出席董事 7 人，实际出席董事 7 人，会议由公司董事长薛永江先生召集和主持，公司监事、高级管理人员列席了 会议。本次会议的召开符合《公司法》和《公司章程》的相关规定。 二、董事会会议审议情况 与会董事对本次会议需审议的议案进行充分讨论，审议通过了以下议案： 1、审议通过了《关于<2024 年度董事会工作报告>的议案》 证券代码：301331 证券简称：恩威医药 公告编号：2025-004 恩威医药股份有限公司 第三届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本议案尚需提交公司 2024 年年度股东大会审议。 2、审议通过了《关于<2024 年度首席执行官工作报告>的议案》 公司首席执行官提交的《2024 年度首席执行官工作报告》，内容包括公司 管理层在 2024 年度经营情况概述、报告期内重点工作 ...

恩威医药股份有限公司 第三届董事会独立董事专门会议第二次会议决议 2025 年 4 月 18 日，恩威医药股份有限公司第三届董事会独立董事专门会议 召开了第二次会议，本次会议通知于 2025 年 4 月 8 日以通讯方式发出，本次会 议应参会独立董事 3 名，实际参会独立董事 3 名。会议由黎春主持召开。本次会 议的召开符合《公司法》和《公司章程》的有关规定，所做决议合法有效。 会议通过决议如下： 出席会议的独立董事签字： 黎春（签字） 彭 刚（签字） 刘娅（签字） 2025 年 4 月 18 日 2 1、审议通过《关于预计公司 2025 年度日常关联交易情况的议案》 经审议，全体独立董事认为：公司 2025 年度拟与关联方发生的日常关联交 易均为公司日常经营活动所需，交易定价以市场价格为依据确定，遵循了客观、 公平、公允原则，符合《公司章程》和《关联交易管理办法》的相关规定，不存 在损害公司及股东特别是中小股东利益的情况，也不会对公司业务的独立性造成 影响。 全体独立董事以同意 3 票，反对 0 票，弃权 0 票，审议并通过此议案。 1 （本页无正文，为《恩威医药股份有限公司第三届董事会独立董事专门会议第二 ...

证券代码：301331 证券简称：恩威医药 公告编号：2025-010 恩威医药股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 恩威医药股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召开第三届 董事会第六次会议和第三届监事会第六次会议，会议审议通过《关于 2024 年度 利润分配预案的议案》，本次利润分配预案尚需提交公司 2024 年年度股东大会 审议批准。现将有关情况公告如下： 一、审议程序 经信永中和会计师事务所（特殊普通合伙）审计，2024 年度公司实现归属于 上市公司股东的净利润为 3,749.75 万元，母公司实现的净利润为 1,840.13 万元。 根据《公司法》及《公司章程》的规定，2024 年计提法定盈余公积金 184.01 万 元，计提任意盈余公积金为 0.00 元。截至 2024 年 12 月 31 日，公司合并报表可 供分配利润为 33,833.58 万元，母公司报表可供分配利润为 14,251.63 万元。按照 合并报表、母公司报表中可供分配利润孰低的原则，公司 ...

一、2025 年中期分红安排 1、中期分红的前提条件为： 公司实施现金分红应同时满足的条件： （1）公司当期实现的归属于上市公司股东的净利润为正值且公司现金充裕， 实施现金分红不会影响公司后续持续经营； 证券代码：301331 证券简称：恩威医药 公告编号：2025-011 恩威医药股份有限公司 关于提请股东大会授权董事会制定并执行 2025 年中期利润分配方案的公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确、 | | --- | | 完整，没有虚假记载、误导性陈述或重大遗漏。 | 恩威医药股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召开第三届 董事会第六次会议，审议通过了《关于提请股东大会授权董事会制定并执行 2025 年中期利润分配方案的议案》。根据《公司法》《上市公司监管指引第 3 号—上 市公司现金分红》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市 公司规范运作》等相关法律法规、规范性文件及《公司章程》《公司上市后三年 分红回报规划》规定，在综合考虑自身发展阶段、盈利水平、重大资金支出安排 以及投资者回报等因素的基础上，为提升上市公司投资价值，与投资者 ...

Financial Performance - The company's operating revenue for 2024 was ¥812,127,431.13, representing a 3.43% increase compared to ¥785,191,289.82 in 2023[20]. - Net profit attributable to shareholders for 2024 decreased by 56.56% to ¥37,497,544.35 from ¥86,312,275.21 in 2023[20]. - The net profit after deducting non-recurring gains and losses was ¥34,729,637.24 in 2024, down 52.80% from ¥73,584,999.39 in 2023[20]. - The company's total assets increased by 12.49% to ¥1,504,528,918.05 at the end of 2024, compared to ¥1,337,497,679.93 at the end of 2023[20]. - The basic earnings per share for 2024 was ¥0.3728, a decrease of 55.59% from ¥0.8394 in 2023[20]. - The cash flow from operating activities for 2024 was ¥78,919,719.83, a decline of 6.06% from ¥84,011,066.56 in 2023[20]. - The total revenue for 2024 reached approximately ¥812.13 million, representing a 3.43% increase from ¥785.19 million in 2023[74]. - The pharmaceutical manufacturing sector contributed ¥808.19 million, accounting for 99.51% of total revenue, with a year-on-year growth of 3.45%[74]. - The gynecological product line generated ¥418.65 million, which is 51.55% of total revenue, showing a significant increase of 15.43% compared to the previous year[74]. - E-commerce sales surged to ¥235.89 million, making up 29.05% of total revenue, reflecting a growth of 37.28% from ¥171.84 million in 2023[74]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 1.80 CNY per 10 shares (including tax) to all shareholders[5]. - The total cash dividend amount for the year is 18,193,744.98 CNY, which represents 100% of the total distributable profit[163]. - The company reported a net profit attributable to shareholders of 37.50 million CNY for 2024, with a total distributable profit of 142.52 million CNY[166]. - For the 2024 profit distribution plan, the company plans to distribute a cash dividend of 1.80 CNY per 10 shares (including tax), totaling approximately 18,193,744.98 CNY[166]. - The company is in a growth phase and aims to maintain a minimum cash dividend ratio of 20% during profit distribution[165]. - The company ensures that minority shareholders have the opportunity to express their opinions and that their legal rights are fully protected[162]. Market and Product Development - The company’s future plans include potential market expansion and new product development initiatives[4]. - The company focuses on the development and sales of proprietary gynecological products, pediatric medications, and respiratory system drugs, with 21 exclusive products currently available[37]. - The company is expanding its product range by leveraging brand and sales channel advantages, targeting diverse therapeutic areas including reproductive, digestive, and respiratory systems[37]. - The company plans to launch several exclusive products in 2025, including "Jian'er Pills," "Ganmao Shu Granules," and "Ren Shen Yang Rong Gao," aimed at addressing various health issues[47]. - The company plans to launch over 20 new products in 2025, including key products like "Jian Er Pills" and "Wu Ji Bai Feng Pills" to enhance market presence[62]. - The company aims to achieve over 100% sales growth in its non-pharmaceutical product line from 2022 to 2024[68]. Compliance and Governance - The company emphasizes the importance of risk awareness regarding industry policy changes, market risks, cost fluctuations, R&D innovation risks, and goodwill impairment risks[5]. - The company is committed to enhancing its governance structure in compliance with relevant laws and regulations, ensuring transparency in information disclosure[121]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with governance standards[124]. - The company maintains complete independence from its actual controllers in terms of business operations, personnel, and financial management[129]. - The company has established a dedicated investor relations management system to enhance communication with investors[128]. - The company has implemented a strict internal control training program for its board members and senior management to enhance governance levels[171]. Environmental Responsibility - The company has maintained compliance with industry standards for wastewater discharge and air pollution control, demonstrating commitment to environmental regulations[178]. - The company has not encountered any major deficiencies in its governance self-inspection actions[176]. - The company invested a total of 3.2564 million yuan in environmental governance and protection, and paid an environmental protection tax of 46,200 yuan during the reporting period[184]. - The company has implemented an automatic environmental monitoring system, including real-time monitoring of wastewater and air pollution, with key parameters such as COD, ammonia nitrogen, pH, and flow rate being monitored[184]. - The company emphasizes environmental protection and adheres to national regulations, promoting green and low-carbon practices in its operations[188]. Employee Relations and Compensation - The total remuneration paid to the board of directors, supervisors, and senior management in 2024 amounted to 4.3993 million yuan[146]. - The company has established a competitive compensation and benefits system, ensuring fair treatment and equal development opportunities for all employees[157]. - The total number of employees at the end of the reporting period was 1,548, with 770 in the parent company and 778 in major subsidiaries[156]. - The workforce consists of 499 production personnel, 774 sales personnel, 28 technical personnel, 25 financial personnel, and 222 administrative personnel[156]. - A total of over 80 training sessions were completed in 2024, with plans for 90 sessions in 2025, focusing on job-specific training needs[159]. Strategic Initiatives - The company plans to continue its focus on innovation and market expansion in the upcoming fiscal year[136]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $30 million allocated for potential deals[140]. - The company will pursue external acquisitions to enhance growth, leveraging its capital and brand advantages[115]. - The company aims to leverage its experienced management team to drive future growth and operational efficiency[136]. - The company is committed to developing 8-10 core products with over 100 million in sales, including key items like Jieer Yin Wash and various traditional Chinese medicines[114].

Financial Performance - The company's revenue for Q1 2025 was CNY 196,499,491.35, representing a 7.10% increase compared to CNY 183,475,935.51 in the same period last year[5] - Net profit attributable to shareholders reached CNY 16,305,126.89, a significant increase of 93.56% from CNY 8,423,929.99 in the previous year[5] - Basic earnings per share rose to CNY 0.1635, up 97.46% from CNY 0.0828 in the previous year[5] - Operating profit for the current period was ¥18,195,945.08, up 73.5% from ¥10,492,562.26 in the previous period[17] - Net profit for the current period was ¥16,305,126.89, representing a 93.5% increase from ¥8,423,929.99 in the previous period[17] Cash Flow - The net cash flow from operating activities was CNY 24,678,125.49, showing a remarkable increase of 306.77% compared to CNY 6,066,863.78 in the same period last year[5] - Cash and cash equivalents at the end of the period totaled ¥293,098,750.80, compared to ¥220,687,086.13 at the end of the previous period[21] - The cash and cash equivalents net increase was CNY 3,874,961.25, a 125.61% improvement compared to a decrease of CNY 15,129,696.08 in the previous year[9] - The company reported a net cash outflow from investing activities of ¥19,974,405.55, worsening from a net outflow of ¥13,052,195.35 in the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,496,270,124.07, a slight decrease of 0.55% from CNY 1,504,528,918.05 at the end of the previous year[5] - Total liabilities decreased to ¥419,765,155.50 from ¥446,857,834.56, a reduction of about 6.07%[16] - The company's equity attributable to shareholders increased to CNY 1,076,504,968.57, reflecting a growth of 1.78% from CNY 1,057,671,083.49 at the end of the previous year[5] - Current assets totaled ¥942,025,659.66, down from ¥952,037,157.23, indicating a decline of approximately 1.26%[15] Inventory and Receivables - Accounts receivable rose to ¥129,280,731.92 from ¥120,242,245.29, marking an increase of approximately 7.93%[15] - The company’s inventory increased slightly from ¥115,551,553.67 to ¥116,623,924.61, reflecting a growth of approximately 0.93%[15] - The company reported a decrease in accounts payable from ¥49,493,170.61 to ¥47,766,193.03, a decline of about 3.49%[16] Investment Activities - The company experienced a 53.03% increase in cash flow from investing activities, amounting to CNY -19,974,405.55, primarily due to increased purchases of financial products[9] - The company’s long-term investments remained stable at ¥374,400.42[15] Accounting Standards - The company plans to implement new accounting standards starting in 2025, which may affect financial reporting[22]

证券代码：301331 证券简称：恩威医药 公告编号：2025-003 恩威医药股份有限公司 关于全资子公司取得换发的《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 有效期至：2025 年 12 月 31 日 编 号：豫 20150079 恩威医药股份有限公司（以下简称：公司）全资子公司河南信心药业有限公司（以 下简称：信心药业）、四川恩威制药有限公司、恩威（江西）制药有限公司于近日取 得了药品监管部门换发的《药品生产许可证》，现将有关情况公告如下： 一、换发的《药品生产许可证》基本信息 1、河南信心药业有限公司 企业名称：河南信心药业有限公司 注册地址：郑州市二七区嵩山南路 81 号嵩山园区综合楼南楼第五层楼 社会信用代码：91410100170007221L 法定代表人：庄严 企业负责人：陈世超 质量负责人：王珏 分类码：AzBz 生产地址和生产范围： 郑州市陇海中路 56 号：片剂，颗粒剂，散剂，丸剂(大蜜丸、水蜜丸、水丸、浓 缩丸、蜡丸)，合剂(口服液)，糖浆剂，煎膏剂(含中药前处理及提取)***四川省成都市 双流区双华路三段 ...

Group 1: Company Overview and Strategy - The Chairman introduced the company's competitive advantages and future development strategies, emphasizing the importance of product quality and brand promotion [2] - The company plans to achieve significant growth in product shipments by the second half of 2025, aiming to enter the top market share within three years [2] Group 2: Product Development and Market Potential - In 2025, the company aims to complete the development and production of over ten key products, including Jian'er Pills and Wujihuai Feng Pills [3] - The total market capacity for the 125 product approvals from Xinxin Pharmaceutical exceeds 15 billion RMB, with expectations for substantial incremental growth [3] Group 3: E-commerce Growth - The company has established a 140-member e-commerce operations team, achieving approximately 50% annual growth in online business over the past five years [3] - Notable products in the personal care category have seen significant sales increases, contributing to the overall growth of the e-commerce segment [3] Group 4: Mergers and Acquisitions - The company has a history of successful acquisitions, including the purchase of Jiangxi Diwei Pharmaceutical in 2017, which resulted in multiple-fold revenue growth for acquired products [4] - Future acquisition strategies will focus on specialty drugs and significant products in niche markets, aiming to influence the company's direction over the next 5 to 10 years [4] - The company is actively monitoring potential acquisition targets that align with its strategic goals for 2024 [4]

证券代码：301331 证券简称：恩威医药 公告编号：2025-002 恩威医药股份有限公司 关于一致行动人取得金融机构增持贷款承诺暨增持公司 股份计划的公告 公司控股股东一致行动人成都杰威企业管理有限公司保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。本公司及董事会全体成员保证公告内容与信息披露义务 人提供的信息一致。 特别提示： 1、恩威医药股份有限公司（以下简称"公司"）控股股东成都恩威投资（集 团）有限公司（以下简称"恩威集团"）一致行动人成都杰威企业管理有限公司 （以下简称"成都杰威/增持主体"）基于对公司未来持续稳定发展的信心和长 期投资价值的认可，为增强投资者信心，成都杰威计划自本公告之日起 6 个月内， 通过集中竞价的方式增持公司A股股份。总体增持金额不低于人民币3,600万元， 不超过人民币 7,200 万元。 公司于近日收到公司控股股东恩威集团一致行动人成都杰威计划增持公司 股份的函，现将有关情况公告如下： 一、增持主体的基本情况 1 1、增持主体的名称：成都杰威企业管理有限公司，为公司控股股东一致行 动人。 2、增持主体已持有本公司股份的数量、占公司总 ...